Novel Conditioning Regimen Achieves 100% 2-Year Survival in Sickle Cell Transplant Study
Key Insights
A prospective multicenter study of 25 sickle cell patients reported 100% 2-year overall survival and 96% 5-year event-free survival using a novel conditioning regimen.
The regimen combined thymoglobulin, thiotepa, cyclophosphamide, fludarabine, and low-dose total body irradiation with no graft failure observed.
Grade III-IV acute graft-versus-host disease incidence was just 4% at one year, with no chronic GVHD reported and 81% of patients off immunosuppression at one year.
A novel conditioning regimen for hematopoietic stem cell transplantation in sickle cell disease (search) has demonstrated exceptional outcomes, including 100% 2-year overall survival and 96% estimated 5-year event-free survival, according to results from a prospective multicenter study published in Bone Marrow Transplant.
The study, led by Alasbali and colleagues, evaluated an intensified yet well-tolerated conditioning strategy in 25 adolescents and adults with severe sickle cell disease (search) across three centers. The median age of participants was 26.7 years, with a median follow-up of 42 months.
Regimen Design and Patient Population
The conditioning protocol comprised thymoglobulin, thiotepa, cyclophosphamide, fludarabine, and low-dose total body irradiation. The majority of patients (88%) received fully matched sibling transplants, while a small proportion underwent transplantation from a one-antigen mismatched sibling donor. Notably, 12% of participants had previously experienced a second graft failure following earlier transplantation, representing a particularly challenging cohort. Stem cell sources included both bone marrow and peripheral blood, reflecting current clinical practice.
Robust Engraftment Without Graft Failure
No graft failure was observed in the study. Donor engraftment was robust, with median whole blood chimerism reaching 100% at day 28 and remaining high at 97% at one year post-transplantation. Among evaluable participants, 81% were able to discontinue immunosuppression one year after transplantation, indicating sustained graft function and durable immune tolerance.
Favorable Safety Profile
The safety profile of the regimen was notably favorable. The one-year incidence of grade III to IV acute graft-versus-host disease (GVHD) was just 4%, with only one reported case. No chronic graft-versus-host disease was observed during the study period. These findings suggest the conditioning approach effectively reduces the risk of severe immune complications while maintaining high engraftment rates.
Clinical Implications
The investigators emphasized that optimal donor engraftment is associated with a lower risk of secondary myeloid neoplasms, underscoring the broader clinical relevance of achieving stable chimerism. While myeloablative human leukocyte antigen-matched related donor hematopoietic stem cell transplantation is a potentially curative treatment for sickle cell disease (search) with survival rates exceeding 90%, the optimal conditioning strategy for older patients has remained uncertain. This study provides evidence supporting the use of this novel regimen in adolescents and adults with severe sickle cell disease, including those undergoing repeat transplantation, and may inform future standards of care.